Browse the evidence

When adipose tissue storage capacity is exceeded, lipids are redirected to the pancreas causing lipotoxicity, beta-cell dysfunction, and type 2 diabetes.

If you have obesity but do not have diabetes, your body may still be successfully storing fat in your adipose tissue. If you have obesity and diabetes, your body may have reached its limit for storing fat safely, causing fat to leak into your pancreas and damage insulin-producing cells. Focus on improving adipose tissue function rather than just weight loss.

Saturated fatty acids induce beta-cell apoptosis and dysfunction through ceramide accumulation and ER stress, whereas minimal levels of fatty acids are required for normal insulin secretion.

Your body needs some fatty acids to function properly, but too much, especially saturated fat, can poison your insulin-producing cells. This happens when your fat storage cells are full, forcing fat into your pancreas. Managing saturated fat intake and supporting fat storage health are key.

Pea protein supplementation (25 g/day for 13 days) does not attenuate exercise-induced muscle damage in older adults following prolonged walking, performing similarly to a placebo.

If you are over 60 and walk long distances, switching to pea protein instead of whey may not help reduce muscle soreness or damage markers. You might need to stick with whey or increase the dose of plant protein.

Short-term (2-week) crossover metabolic ward trials without washout periods are invalid for determining chronic macronutrient effects on energy intake and body fat due to massive, differential carry-over effects from physiologic adaptation.

Do not rely on short-term (under 4-6 weeks) diet studies to predict long-term weight loss outcomes. The body's metabolic adaptation to macronutrient changes (like ketosis or insulin shifts) takes weeks to months. Short trials often measure transient adaptation rather than chronic effects, leading to misleading conclusions about which diet is superior for fat loss.

Accelerometer-derived summary metrics (MIMS-unit, AAI, MAD, ENMO) derived from raw data provide greater comparability across different device manufacturers and models than traditional proprietary activity counts.

If you are a researcher, stop relying on proprietary 'counts' to compare studies. Use open-source raw data algorithms (like MIMS-unit or AAI) to ensure your findings are comparable across different device brands. If you are a consumer, understand that 'steps' or 'activity scores' from different brands are not mathematically equivalent, even if they look similar.

Prolonged use of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for 3 years or more can enhance beta-cell function.

For those who cannot or will not undergo surgery or strict dieting, long-term GLP-1 agonist therapy (3+ years) may help preserve your pancreas's insulin-producing capacity. This is a disease-modifying effect, not just glucose lowering.

Cardiac diastolic function, specifically the E/e' ratio and Left Atrial Volume Index (LAVI), significantly moderates the reduction in relative peak oxygen uptake in Type 2 Diabetes patients.

For T2D patients, standard cardiac checks might miss the root cause of exercise intolerance. If you struggle with exercise despite normal ejection fraction, ask about diastolic function (E/e' ratio). Addressing this through specific training (like high-intensity interval training, as suggested by the authors) may be more effective than generic advice.

GLP-1 receptor agonists increase perioperative aspiration risk due to delayed gastric emptying, requiring specific holding protocols before elective surgery.

If you are having elective surgery while taking GLP-1 medications, tell your surgeon and anesthesiologist. You may need to hold your medication before surgery to reduce the risk of aspiration. Follow the specific holding instructions provided by your medical team.

SGLT2 inhibitors reduce blood pressure and cardiovascular risk, potentially through central sympatho-inhibition, but do not necessarily reduce muscle sympathetic nerve activity (MSNA) in humans.

SGLT2 inhibitors (like Jardiance or Farxiga) lower blood sugar and protect the heart. While they work by removing glucose through urine, they may also have subtle effects on brain pathways that help lower blood pressure.

Tirzepatide (a dual GIP/GLP-1 receptor agonist) significantly improves hepatic steatosis and increases the likelihood of MASH resolution without worsening fibrosis in patients with non-cirrhotic MASH.

If you have MASH without cirrhosis, ask your doctor about tirzepatide. Clinical trials show that weekly injections of 5-15mg can significantly resolve MASH and improve liver fat without worsening fibrosis. This is a promising option for managing liver health in addition to blood sugar and weight.

Resmetirom is approved for adults with non-cirrhotic MASH and advanced liver fibrosis (stage ≥ 2) and has shown histological efficacy in addressing steatohepatitis and fibrosis.

If you have MASH with advanced fibrosis but no cirrhosis, ask your doctor about resmetirom. It is an approved treatment that has been shown to improve both steatohepatitis and fibrosis with a favorable safety profile.

Bariatric surgery significantly reduces the risk of developing heart failure and improves mortality in patients with existing heart failure and obesity.

For severe obesity, bariatric surgery is a highly effective treatment that can prevent heart failure and significantly improve survival in those who already have it. It is safe and can even be used as a bridge to heart transplantation in severe cases. Consult with a bariatric surgeon and cardiologist to see if you are a candidate.

GLP-1 RAs improve histological markers of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and reduce liver fat in patients with MASLD, MetALD, and ALD.

If you have fatty liver disease (MASLD/MASH), GLP-1 medications like Semaglutide or Liraglutide can significantly improve liver inflammation and fat content, often leading to MASH resolution. This is especially beneficial if you also have obesity or Type 2 Diabetes. Discuss these options with your hepatologist, noting that while they improve liver histology, they may not always reverse advanced fibrosis.

GLP-1 receptor agonist therapy causes a significant increase in resting heart rate (RHR) during the initial 12 weeks of treatment, which is primarily mediated by a reduction in heart rate variability (HRV).

If you start a GLP-1 medication (like semaglutide or tirzepatide), expect your resting heart rate to increase by about 3 beats per minute over the first 3 months. This is a normal, mediated response involving your autonomic nervous system (HRV), not necessarily a sign of heart damage. If you use a wearable, track this trend, but consult your doctor if the increase is extreme or accompanied by other symptoms.

SGLT2 inhibitors improve vascular function by reducing arterial stiffness, improving endothelial function (flow-mediated dilation), and reducing inflammation and oxidative stress.

These drugs don't just lower sugar; they physically improve the health of your blood vessels by making them more flexible and reducing the chemical stress (inflammation/oxidative stress) that damages them over time.

Bariatric surgery, specifically Roux-en-Y gastric bypass (RYGB), is a highly effective treatment for severe obesity, providing rapid and durable weight loss, though it carries risks of adverse events and nutritional deficiencies.

For individuals with severe obesity (BMI >40 or >35 with comorbidities), bariatric surgery like RYGB is a highly effective, durable treatment. It is not a cosmetic procedure but a medical intervention for severe disease. Patients must be prepared for lifelong nutritional monitoring to prevent deficiencies.

The reduction in schizophrenia risk associated with GLP-1 receptor agonists is mediated by body mass index (BMI) rather than glycemic control.

The mental health benefits of GLP-1 drugs for schizophrenia risk appear to come from weight loss, not from lowering blood sugar. This means that interventions focusing on weight management (whether through GLP-1 drugs or other means) may be the key to reducing this specific psychiatric risk. It highlights the importance of addressing obesity in mental health prevention strategies.

Peripheral GLP-1 receptor agonists (GLP-1RAs) exert brain-mediated anorectic effects primarily via access to circumventricular organs (CVOs) like the area postrema and median eminence, rather than crossing the blood-brain barrier (BBB) or blood-cerebrospinal fluid barrier (BCB).

GLP-1 medications like Semaglutide and Liraglutide reduce appetite by signaling from the gut to specific brain regions (CVOs) via the vagus nerve, rather than crossing into the brain tissue itself. This explains why they are effective for weight loss even though very little drug actually enters the cerebrospinal fluid.

Body weight stigma acts as a significant barrier to healthcare engagement and long-term weight management success.

If you feel judged by healthcare providers, it is a common and valid experience that can hinder your care. Seek out providers who practice weight-inclusive or stigma-informed care. Addressing the psychological burden of stigma is a crucial part of effective obesity management.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) cause dose-dependent gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) primarily during dose escalation, leading to discontinuation in 3-17% of non-diabetic users.

If you are using a GLP-1 medication like semaglutide or tirzepatide, expect gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These symptoms are common but usually mild and transient. To manage them, follow a slow titration schedule, eat smaller, low-fat meals, and stay hydrated. Most people adapt over time, but if side effects are severe, consult your doctor about adjusting the dose.

Intermittent Hypoxia (IH) is a key pathogenic factor in OSA that drives cardiovascular and metabolic disease through vascular remodelling, atherosclerosis, and insulin resistance, independent of obesity.

The repeated drops in oxygen during sleep (Intermittent Hypoxia) are what actually damage your heart and metabolism, not just the breathing stops themselves. Managing OSA is crucial to prevent this cycle of damage.

Lifestyle interventions (diet and exercise) alone are insufficient for the majority (80%) of patients with obesity and fail to produce sustained weight loss without addressing the underlying biological disease mechanisms.

If you have obesity, relying solely on diet and exercise is likely to fail for you because your body's biological regulation of weight is disrupted. This is not your fault. You need medical treatment (pharmacotherapy or surgery) to address the biology first; lifestyle changes are only useful for maintenance after the biological drivers are managed.

Overweight status (BMI 25-<30) is not associated with increased risk for most cardiovascular outcomes and may have a neutral or slightly protective effect on all-cause mortality compared to normal weight.

Being overweight is not as strongly linked to heart disease or death as obesity. While weight management is still beneficial, the urgency is lower for overweight individuals compared to those with obesity. Focus on overall health metrics rather than just weight.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and tirzepatide induce significant lean mass loss (muscle wasting) alongside fat mass loss, which exacerbates sarcopenia and frailty in patients with advanced heart failure.

If you have heart failure and are using GLP-1RAs (like Ozempic or Wegovy), be aware that you will likely lose muscle along with fat. To protect your strength, prioritize high-protein foods and engage in resistance exercise regularly. Discuss these risks with your doctor to balance heart benefits against muscle loss.